W, T., K, R., SMA, P., B, S., S, K., P, P. V., . . . S, V. (2021). LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer. Cell death discovery, 7(1), 216. https://doi.org/10.1038/s41420-021-00603-z
Chicago Style (17th ed.) CitationW, Tang, et al. "LIF/LIFR Oncogenic Signaling Is a Novel Therapeutic Target in Endometrial Cancer." Cell Death Discovery 7, no. 1 (2021): 216. https://doi.org/10.1038/s41420-021-00603-z.
MLA (9th ed.) CitationW, Tang, et al. "LIF/LIFR Oncogenic Signaling Is a Novel Therapeutic Target in Endometrial Cancer." Cell Death Discovery, vol. 7, no. 1, 2021, p. 216, https://doi.org/10.1038/s41420-021-00603-z.
Warning: These citations may not always be 100% accurate.
